News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
Dec 06, 2012DURECT Announces Pricing of Public Offering of Common StockPrinter Friendly Version
Nov 13, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Nov 05, 2012DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 30, 2012DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference CallPrinter Friendly Version
Aug 21, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 06, 2012DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
Aug 06, 2012DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative AnalgesiaPrinter Friendly Version
Jul 26, 2012DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference CallPrinter Friendly Version
May 03, 2012DURECT Corporation Announces First Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
May 03, 2012DURECT Announces Issuance of U.S. Patents Covering ORADUR® TechnologyPrinter Friendly Version
Apr 25, 2012DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference CallPrinter Friendly Version
Mar 29, 2012DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™Printer Friendly Version
Mar 01, 2012DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial ResultsPrinter Friendly Version
Feb 24, 2012DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference CallPrinter Friendly Version
Feb 23, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Feb 07, 2012DURECT to Present at the BIO CEO & Investor ConferencePrinter Friendly Version
Jan 30, 2012DURECT Receives Back European Product Rights to POSIDUR™Printer Friendly Version
Jan 05, 2012DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)Printer Friendly Version